Total Payments
$49,532
2024 Payments
$2,898
Companies
13
Transactions
165
Payment Breakdown by Category
Research$27,579 (55.7%)
Travel$16,315 (32.9%)
Food & Beverage$5,639 (11.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $27,579 | 25 | 55.7% |
| Travel and Lodging | $16,315 | 59 | 32.9% |
| Food and Beverage | $5,639 | 81 | 11.4% |
Payments by Type
Research
$27,579
25 transactions
General
$21,953
140 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $24,015 | 22 | $0 (2023) |
| Eisai Inc. | $7,479 | 66 | $0 (2024) |
| Biogen, Inc. | $3,617 | 3 | $0 (2023) |
| Novo Nordisk AS | $3,597 | 13 | $0 (2022) |
| Merck Sharp & Dohme LLC | $3,396 | 29 | $0 (2023) |
| PFIZER INC. | $1,582 | 5 | $0 (2018) |
| Janssen Research & Development, LLC | $1,545 | 8 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $1,281 | 3 | $0 (2024) |
| Genentech, Inc. | $1,197 | 3 | $0 (2018) |
| Allergan Inc. | $1,174 | 5 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,898 | 19 | Eisai Inc. ($1,617) |
| 2023 | $1,814 | 12 | Merck Sharp & Dohme LLC ($988.49) |
| 2022 | $9,251 | 33 | Eli Lilly and Company ($6,117) |
| 2021 | $9,917 | 5 | Eli Lilly and Company ($9,917) |
| 2020 | $1,016 | 7 | Eli Lilly and Company ($549.36) |
| 2019 | $11,812 | 22 | Eli Lilly and Company ($4,909) |
| 2018 | $9,556 | 46 | Merck Sharp & Dohme Corporation ($2,377) |
| 2017 | $3,268 | 21 | PFIZER INC. ($1,570) |
All Payment Transactions
165 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/12/2024 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $49.95 | General |
| 09/12/2024 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $47.25 | General |
| 09/12/2024 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $36.59 | General |
| 09/12/2024 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $24.30 | General |
| 09/11/2024 | Eisai Inc. | — | Travel and Lodging | Cash or cash equivalent | $210.67 | General |
| 09/11/2024 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $116.52 | General |
| 09/11/2024 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $51.98 | General |
| 09/11/2024 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $49.28 | General |
| 09/11/2024 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $43.69 | General |
| 09/11/2024 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $24.30 | General |
| 09/11/2024 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $22.95 | General |
| 09/10/2024 | Eisai Inc. | — | Travel and Lodging | Cash or cash equivalent | $526.81 | General |
| 09/10/2024 | Eisai Inc. | — | Travel and Lodging | Cash or cash equivalent | $210.67 | General |
| 09/10/2024 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $118.01 | General |
| 09/10/2024 | Eisai Inc. | — | Travel and Lodging | Cash or cash equivalent | $78.30 | General |
| 09/10/2024 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $5.54 | General |
| 03/29/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | In-kind items and services | $645.00 | General |
| 03/29/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | In-kind items and services | $328.37 | General |
| 03/29/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $308.03 | General |
| 10/26/2023 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $130.39 | General |
| 06/15/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $457.36 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/15/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $56.32 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/15/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $46.61 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/15/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $46.61 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/15/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $32.63 | General |
| Category: CARDIOVASCULAR | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $11,225 | 3 |
| A PHASE 2 STUDY OF ONCE-DAILY LY3502970 COMPARED WITH PLACEBO IN PARTICIPANTS WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES | Eli Lilly and Company | $4,765 | 2 |
| A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $4,548 | 1 |
| A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities | Biogen, Inc. | $3,427 | 1 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $1,745 | 2 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) | Eli Lilly and Company | $669.97 | 3 |
| A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | Eli Lilly and Company | $520.00 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | Eli Lilly and Company | $163.00 | 1 |
| ASSESSMENT OF SAFETY AND EFFICACY OF SUBCUTANEOUS REMTERNETUG IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $153.00 | 1 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy, Tolerability, and Safety Study of DFN-15 in Episodic Migraine With or Without Aura Oral Celecoxib | Dr.Reddy's Laboratories,Inc. | $112.36 | 2 |
| A PHASE 3, OPEN-LABEL, PARALLEL-GROUP, 2-ARM STUDY TO INVESTIGATE AMYLOID PLAQUE CLEARANCE WITH DONANEMAB COMPARED WITH ADUCANUMAB-AVWA IN PARTICIPANTS WITH EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $54.06 | 2 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH EPISODIC MIGRAINE - THE EVOLVE-1 STUDY | Eli Lilly and Company | $52.80 | 1 |
| DONANEMAB FOLLOW-ON STUDY: SAFETY, TOLERABILITY, AND EFFICACY IN SYMPTOMATIC ALZHEIMER'S DISEASE WITH VALIDATION OF REMOTE NEUROPSYCHOLOGICAL ASSESSMENTS | Eli Lilly and Company | $50.00 | 1 |
| EX9536-4388 | Novo Nordisk AS | $50.00 | 1 |
| A PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | Eli Lilly and Company | $21.46 | 1 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $21.00 | 1 |
| ASSESSMENT OF SAFETY TOLERABILITY AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $0.64 | 1 |
About Dr. John Scott, MD
Dr. John Scott, MD is a Family Medicine healthcare provider based in Glen Allen, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1538103114.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Scott, MD has received a total of $49,532 in payments from pharmaceutical and medical device companies, with $2,898 received in 2024. These payments were reported across 165 transactions from 13 companies. The most common payment nature is "" ($27,579).
Ad
Practice Information
- Specialty Family Medicine
- Location Glen Allen, VA
- Active Since 06/15/2006
- Last Updated 11/02/2011
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1538103114
Products in Payments
- TALTZ (Drug) $4,548
- Non-Covered Product (Drug) $1,267
- MK-7264 (Drug) $1,208
- V160 (Biological) $1,170
- Wegovy (Drug) $50.00
- XTANDI (Drug) $11.83
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Glen Allen
Helen Adams, Md, MD
Family Medicine — Payments: $9,668
Family Medicine $9,668
Anuradha Gonuguntla, Md, MD
Family Medicine — Payments: $8,269
Family Medicine $8,269
Stephen Read, M.d, M.D
Family Medicine — Payments: $2,022
Family Medicine $2,022
Faiza Akbar, M.d, M.D
Family Medicine — Payments: $1,893
Family Medicine $1,893
Dr. Kathryn Rose-Vallejo, M.d, M.D
Family Medicine — Payments: $1,525
Family Medicine $1,525
Thanh-Truc Lieng, M.d, M.D
Family Medicine — Payments: $1,450
Family Medicine $1,450